EU Approves Merck KGaA (MKGAF.PK)'s Erbitux For A Subtype Of Cancer
12/23/2013 7:21:16 AM
The European Commission has approved the use of Merck KGaA (MRK.XE) drug Erbitux for treatment of a subtype of cancer, the German pharmaceutical company said Monday. MAIN FACTS: - The Commission has approved an update of the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer. - The approval follows the positive opinion from the Committee for Medicinal Products for Human Use.
Help employers find you! Check out all the jobs and post your resume.
comments powered by